openPR Logo
Press release

Huge Investment in mTOR Inhibitors Market Expected to Witness the Highest Growth 2025 | International Key Vendors – GSK, LC Lab, Teva, Exelixis, Novartis Oncology, Pfizer

07-31-2020 06:54 PM CET | Health & Medicine

Press release from: Business Industry Reports

mTOR Inhibitors Market

mTOR Inhibitors Market

Global mTOR Inhibitors Market Synopsis:

The exclusive research report on the Global mTOR Inhibitors Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global mTOR Inhibitors Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.

According to the market research study, Mammalian Target Of Rapamycin (mTOR) is a protein that regulates vital cell growth processes in a living organism. mTOR acts as a communication command centre in human body by receiving external signals from growth factors, hormones, proteins and transfer the signal to ON or OFF mode for the cell to grow and divide. Many human cancer causes due to dysregulation of mTOR signaling and can confer higher susceptibility to mTOR inhibitors. Disregulation of mTOR signaling includes PI3K amplification/mutation, Phosphatase and Tensin Homolog (PTEN) loss of function, eIF4E protein over expression and over expression of protein kinase B. Thus, rising prevalence of various cancers (lung cancer, prostate cancer, breast cancer and cervical cancer) the Global mTOR Inhibitors Market is experiencing a significant growth.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/273420 .

Significant points in table of contents: Market Definition, Market Overview, Business Introduction, Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation (Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost Analysis, and Conclusion. The mTOR Inhibitors Market is segmented based on Product, source, application and Regions. On the basis of product, the market is sub-segmented.

On the basis of geographic analysis, North America and Europe was observed to be the largest mTOR Inhibitors Market due to major market players are based in these regions. Moreover, North America and Europe accounted for the highest number of diagnosis cases performed with respect to various cancer every year. Additionally, favorable initiatives taken by the federal government also accounted for the mTOR Inhibitors Market growth in North American and European regions. APAC is considered as an untapped market due to lack of proper healthcare facilities in some Asian countries.

Top Major Key Players in the Global mTOR Inhibitors Market:

1 LC Laboratories

2 Teva Pharmaceutical Industries

3 Exelixis

4 Novartis Oncology

5 Pfizer

6 GSK and More……………..

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global mTOR Inhibitors Market Report 2020” @ https://www.businessindustryreports.com/buy-now/273420/single .

Product Type Segmentation

1 Rapamune

2 Torisel

3 Afinitor

4 Zortress

Industry Segmentation

1 Tumor Treatment

2 Kidney Transplant

International Medical Industry News:

GlaxoSmithKline (GSK) (July 20, 2020) - GSK and CureVac announce strategic mRNA technology collaboration - GlaxoSmithKline plc and CureVac today announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform.

mRNA (messenger RNA) technology is a rapidly progressing, cutting-edge platform for the development of new vaccines and medicines, potentially expanding the range of diseases which can be prevented or treated, while also promising to significantly speed up development and manufacturing. mRNA enables protein synthesis in the human body, carrying the genetic code required for cells to manufacture and express proteins. By using mRNA technology in vaccines and medicines, specific proteins, or antigens, can be produced by the body’s own cells, enabling the human immune system to prevent or fight disease.

CureVac’s leadership in mRNA technology, along with its mRNA manufacturing capability, complements GSK's existing scientific leadership in vaccines, including GSK's own self-amplifying mRNA (SAM) vaccine technology platform, and further builds on GSK's growing capability in mAbs innovation, aligned to its R&D focus on the science of immunology. Advancing mRNA-based vaccine and treatment technologies are also expected to play a role in further improving response against future pandemics.

Roger Connor, President GSK Vaccines, said: “GSK’s self-amplifying mRNA (SAM) vaccine technology has shown us the potential of mRNA technology to advance the science of vaccine development, and CureVac’s experience complements our own expertise. Through the application of mRNA technology, including SAM, we hope to be able to develop and scale up advanced vaccines and therapies to treat and prevent infectious diseases quicker than ever before.” 

Dr. Franz-Werner Haas, acting Chief Executive Officer of CureVac, added: “We are delighted to partner with GSK.  With this collaboration, we are gaining a world-class partner whose expertise and global footprint will allow us to further develop and translate the value of our platform into potential products for the world.”

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/273420 .

Major Points in Table of Contents:

Global mTOR Inhibitors Market Report 2020

1 mTOR Inhibitors Product Definition

2 Global mTOR Inhibitors Market Manufacturer Share and Market Overview

2.1 Global Manufacturer mTOR Inhibitors Shipments

2.2 Global Manufacturer mTOR Inhibitors Business Revenue

2.3 Global mTOR Inhibitors Market Overview

2.4 COVID-19 Impact on mTOR Inhibitors Industry

3 Manufacturer mTOR Inhibitors Business Introduction

3.1 LC Laboratories mTOR Inhibitors Business Introduction

3.2 Teva Pharmaceutical Industries Ltd. mTOR Inhibitors Business Introduction

3.3 Exelixis mTOR Inhibitors Business Introduction

3.4 Novartis Oncology mTOR Inhibitors Business Introduction

3.5 Pfizer mTOR Inhibitors Business Introduction

3.6 GSK mTOR Inhibitors Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Huge Investment in mTOR Inhibitors Market Expected to Witness the Highest Growth 2025 | International Key Vendors – GSK, LC Lab, Teva, Exelixis, Novartis Oncology, Pfizer here

News-ID: 2101231 • Views: 315

More Releases from Business Industry Reports

2020-2025 Neoantigen Targeted Therapies Market to witness astonishing growth wit …
Global Neoantigen Targeted Therapies Market Synopsis: The report covers a forecast and an analysis of the Neoantigen Targeted Therapies Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Neoantigen Targeted Therapies Market along with the impact they have
Outstanding Scope of Nasojejunal Tube Market is Estimated to Grow Incredible CAG …
Overview of Global Nasojejunal Tube Market: This report provides in-depth study of “Global Nasojejunal Tube Market 2020” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Nasojejunal Tube Market report also provides an in-depth survey of key players in the market organization. The 'Global Nasojejunal Tube Industry, Market Research Report' is a professional and in-depth study on the current state of the global Nasojejunal Tube Market with a
SWOT Analysis of mRNA Treatment Market Excessive Growth Opportunities Estimated …
The exclusive research report on the Global mRNA Treatment Market 2020 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global mRNA Treatment Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe. Overview of Global mRNA Treatment Market: This report studies the Global mRNA Treatment Market over the forecast
Mobile Cardiac Telemetry Systems Market to Exhibit Impressive Growth by 2025: In …
BusinessIndustryReports has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Mobile Cardiac Telemetry Systems Market” Research Report 2020 provides an in-depth analysis of the Mobile Cardiac Telemetry Systems with the forecast of market size and growth. The analysis includes addressable market, market by volume, market share by business type and by segment (external and in-house). The research study examines the Mobile Cardiac Telemetry

All 5 Releases


More Releases for Inhibitors

Global Protein Kinase Inhibitors Market Research Report
This report studies the global Protein Kinase Inhibitors market status and forecast, categorizes the global Protein Kinase Inhibitors market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Bayer Astra Zeneca Roche Teva Apotex Novartis Glaxosmithkline Pfizer Geographically, this report studies the top
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
AKT Inhibitors - Pipeline Insights 2017
The “AKT Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of AKT drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential AKT inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and
AKT Inhibitors - Pipeline Insights 2017
The “AKT Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of AKT drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential AKT inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and
CDK Inhibitors Therapeutics Pipeline Analysis 2017
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation. Explore Report at: www.psmarketresearch.com/market-analysis/cdk-inhibitors-therapeutics-pipeline-analysis USFDA granted Breakthrough Therapy Designation to a drug